An engineered stem cell therapy reversed new-onset Type 1 diabetes in mice by shifting the immune system away from attacking ...
Patients may not know that these treatments are experimental or about the risks they may pose. The latest in AJC's ...
Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose (MAD) of ABS-201 in ...
Zacks Investment Research on MSN
VKTX stock jumps on Phase I study initiation for new obesity drug
Shares of Viking Therapeutics VKTX rose about 9% on Wednesday after the company expanded its obesity pipeline by advancing a ...
Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer’s disease (AD) research, including lecanem ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...
Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instructions can produce weight loss and blood glucose control in murine models that lasts ...
Over the past decades, some medical researchers and neuroscientists have been exploring the possible therapeutic effects of ...
Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...
Two critical Cursor IDE vulnerabilities, dubbed DuneSlide, let prompt injection break the editor's command sandbox with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results